● HyaFilia SMV sales begin, launching event held
● Approximately 150 local distributors and medical staff participated, promoting the excellence of HyaFilia SMV
● Following Thailand, we will enter Indonesia, China, and Brazil within the year
CHAMEDITECH (CEO Kim Sok-jin), an affiliate of CHA Biotech, entered the Thailand aesthetic market by introducing HA (hyaluronic acid) filler ‘HyaFilia SMV’.
CHAMEDITECH obtained product approval for the HyaFilia SMV product from the Thailand Food and Drug Administration in October 2023. Subsequently, the company signed a contract with Vitapharm Asia Co., Ltd., a beauty and plastic surgery medical device distribution company, as a distribution partner and began full-scale sales in January.
CHAMEDITECH held a launching event to commemorate the launch of HyaFilia SMV in Thailand. This event, held at the Eastin Grand Hotel in Bangkok on January 22, was attended by Kim Sok-jin, CEO of CHAMEDITECH, CEO of Vitapharm Asia, and about 150 local Thailand medical staff. On this day, Daegu Dr. Tune's Clinic director Na Ji-hye attended the event as a speaker, publicized the excellence of HyaFilia SMV products, and explained the treatment protocol using the product.
Thailand has the second largest beauty and plastic surgery market in Asia after China. Recently, the beauty and plastic surgery market such as botox and filler is also growing rapidly. Starting with the launch of HyaFilia SMV, CHAMEDITECH plans to increase its market share by sequentially introducing HA filler products such as HyaFilia SMV+ and Dorothy.
CHAMEDITECH is also expanding our presence in the global market beyond Thailand. CHAMEDITECH plans to expand its influence in the global market by completing the product approval and launch of HyaFilia SMV in Indonesia, China, and Brazil within this year.
'HyaFilia' is a hyaluronic acid filler developed by CHAMEDITECH, and is a product that first established its position in the overseas market by exporting it to overseas countries such as Europe and the Middle East. Based on its own technology, CHA-HEART (Cross-linked Hyaluronic Acid of Hight concentration Emulsion Arrangement & Refinement Technology), CHAMEDITECH minimized the chemical cross-linking material BDDE (ButanDiol Diglycidyl Ether) to reduce the risk of cytotoxicity and increase safety.
Kim Sok-jin, CEO of CHAMEDITECH, said, “We plan to expand our presence in the global market by continuously discovering local partners. Based on our excellent products and technology, we will quickly expand the market share of HyaFilia, CHAMEDITECH’s filler brand, in the global market.” He said.